Anupam Rasayan India

ANURAS is trading at ₹1,150.00 as of November 5, 2026, exhibiting a complex technical structure where short-term price action conflicts with broader trend indicators. On the daily chart, the stock has positioned itself above its 20-period EMA and SMA, suggesting immediate resilience, yet it remains firmly below the 50-period EMA, 200-period SMA, and Supertrend, which are all bearish. This divergence is corroborated by an ADX of 30.85, indicating that the current downward trend retains established strength despite the recent +0.4% daily gain.

On weekly and monthly horizons, the setup is uniformly bearish; the price sits below all major moving averages and the Supertrend on both timeframes. The monthly ADX of 63.84 signals strong conviction in the longer-term downtrend. Participation metrics show mixed signals: while a high-participation event was noted on November 5, volume ratios remain low (0.15), and downside events have outnumbered positive attention events significantly over the past month. The stock is currently located in the upper-middle of its 20-day range (+67.4%) but near the lower-middle of its 252-day range (+26.7%).

Key levels to monitor include resistance at ₹1,152.93 (0.26% above) and support at ₹1,144.97 (0.44% below). A break below ₹1,144.97 would likely reconfirm the bearish momentum, while a sustained move above ₹1,152.93 with increased participation would be required to challenge the immediate overhead supply.

Anupam Rasayan India Limited (ANURAS) reported unaudited financial results for the quarter and half-year ended September 30, 2026, on November 6, 2026. A material change in the company's structure is the consolidation of Bliss GVS Pharma Ltd, effective September 28, 2026, which added INR 10,223.94 million in provisional goodwill to the balance sheet. This acquisition significantly expanded the consolidated top line; standalone revenue from operations was INR 3,971.87 million for the quarter, while consolidated revenue reached INR 8,059.35 million. For the half-year, standalone revenue was INR 7,259.92 million versus consolidated revenue of INR 14,609.15 million. Profit after tax also reflects this scale increase, with consolidated PAT at INR 649.69 million (quarter) and INR 1,161.83 million (half-year), compared to standalone figures of INR 456.50 million and INR 776.55 million respectively. Market data as of November 5, 2026, shows the stock trading at ₹1,150.00, up from ₹1,144.00.

Anupam Rasayan India Limited (ANURAS) reported unaudited financial results for the half-year ended September 30, 2026, on November 6, 2026. The company’s consolidated revenue from operations doubled to ₹14,609.15 million (H1FY27), driven by the acquisition of Bliss GVS Pharma Ltd effective September 28, 2026. This acquisition added INR 10,223.94 million in provisional goodwill and increased H1 consolidated profit after tax to ₹1,161.83 million. Standalone figures showed H1 revenue of ₹7,259.92 million and PAT of ₹776.55 million.

Governance and capital structure updates include a final dividend of ₹1.5 per equity share approved at the AGM held on September 30, 2026. Shareholding data as of September 30, 2026, indicates promoter holding remains stable at 59.07%, with public holding at 40.93%. Additionally, Catalyst Trusteeship Limited filed disclosures under Regulation 29 on October 27, 2026, regarding acquisitions of ANURAS equity shares acting as a debenture trustee.

Anupam Rasayan India (ANURAS) is executing a rapid expansion phase, marked by a sharp rebound in sales and profitability. For the quarter ended Q1 FY2026-27, revenue from operations rose sequentially to ₹654.98 crore, while Profit Before Tax (PBT) increased to ₹69.68 crore from ₹56.07 crore in Q4 FY2025-26. This follows a strong full-year trajectory where FY2025-26 sales reached ₹2,365 crore, up significantly from ₹1,437 crore in FY2024-25, with net profit growing from ₹160 crore to ₹222 crore.

However, this growth is accompanied by rising financial leverage and interest costs. Borrowings increased steadily from ₹1,069 crore in Mar 2024 to ₹1,867 crore in Mar 2026. Consequently, finance costs rose to ₹49.19 crore in Q1 FY2026-27, and annual interest expenses climbed to ₹149 crore in Mar 2026. While operating efficiency has improved—with Cash Conversion Cycle dropping sharply to 377 days in Mar 2026 from 715 days in Mar 2025—the company remains capital-intensive, evidenced by Fixed Assets nearly doubling to ₹3,713 crore over two years.

Earnings quality shows mixed signals; CFO/EBITDA conversion improved to 72% in Mar 2026 after a low of 3% in Mar 2025, suggesting better cash realization recently. Return on Capital Employed (ROCE) has stabilized at 7% for the last two years, indicating that current asset growth is not yet translating into higher returns. Promoter holding remains stable at 59.07%, while Foreign Institutional Investors (FIIs) increased their stake to 8.65% in Sep 2026.

Technical indicators for Anupam Rasayan India (NSE: ANURAS) as of 5 November 2026 present a predominantly cautionary setup, characterized by sustained downward momentum across multiple timeframes. The stock is trading at ₹1,150.0, with daily, weekly, and monthly SuperTrend signals all indicating a bearish trend. Short-term moving averages are declining sharply; the 20-day SMA slope has fallen by -6.35 points over five days, while the 50-day SMA slope has dropped by -9.14 points, signaling weakening intermediate-term support. On a weekly basis, the 20-day EMA slope has plunged by -37.98 points, reflecting accelerated selling pressure. Relative Strength Index components show the minus DI (18.19 on daily, 26.98 on weekly) consistently outweighing the plus DI, confirming seller dominance. Performance metrics further underscore this deterioration, with the stock down -13.3% year-to-date and -15.4% over the last six months. The current drawdown stands at -16.4%, approaching the maximum historical drawdown of -20.2%. While immediate resistance is tight between ₹1,152.93 and ₹1,168.43, the broader technical structure suggests limited upside traction until these downtrend slopes stabilize.